Obesity

Health Tech

Why One CEO Thinks Drugs Won’t Be Able to Solve the Obesity Crisis

New research found that there are no racial disparities in weight loss results among patients taking obesity drugs. However, the study found that people of color have less access to services like behavioral care or surgical interventions, which are often needed in order for patients to lose weight and keep it off. To tackle this issue, Enara Health CEO Rami Bailony argued that the U.S. healthcare system must innovate the way it dispenses weight loss drugs, employing a more holistic care approach.

By Katie Adams
MedCity Influencers, BioPharma

Are Registered Dietitians the Key To Optimizing Weight Loss With GLP-1s?

Prescriptions for GLP-1s are soaring, but fewer than a third of people prescribed the costly drugs will continue taking them one year later without personalized support. Without the expert guidance of a registered dietitian, you risk not achieving the significant clinical benefits these drugs offer and forfeiting the potential for sustainable, transformative health outcomes.

By Gretchen Zimmermann
sponsored content

A Deep-dive Into Specialty Pharma

A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.

By PurpleLab
Consumer / Employer

Walgreens Exec: Reimbursement Models Need to Catch Up with GLP-1 Demand

Walgreens is seeing “an enormous amount of demand” for injectable weight loss drugs, its president of U.S. healthcare said during the Reuters Total Health conference in Chicago. He declared that the healthcare industry needs to come up with a reimbursement model “that correctly compensates pharmacists and others” to administer these drugs. In his view, reimbursement hasn't caught up with the demand.

By Katie Adams